Ozempic, Wegovy, Mounjaro and Zepbound: brands and active ingredients

Four well-known brand names contain just two active ingredients. Ozempic and Wegovy contain semaglutide. Mounjaro and Zepbound contain tirzepatide. FDA approves each of these brands separately, each for its own set of uses, and each has its own label.

This page lists them from FDA's own records, with a link to each label, so you can check what you have. It doesn't cover doses, strengths, side effects or how the products compare. For anything about your own treatment, ask your prescriber or pharmacist.

The brands at a glance

Semaglutide also comes as tablets, sold under the Ozempic, Wegovy and Rybelsus names, so those are included. Every row was checked against Drugs@FDA and DailyMed on October 25, 2026.

Semaglutide and tirzepatide brands: active ingredient, maker and application, dosage form and route, approved use and FDA label
Brand	Active ingredient	Maker and application	Dosage form and route	Approved use (label section 1, shortened)	FDA label
Ozempic (injection)	Semaglutide	Novo Nordisk (NDA 209637)	Injection (solution), subcutaneous	In adults with type 2 diabetes: with diet and exercise, to improve glycemic (blood sugar) control; to reduce the risk of major adverse cardiovascular events in those with established cardiovascular disease; and to reduce the risk of sustained decline in kidney function (eGFR), end-stage kidney disease and cardiovascular death in those with chronic kidney disease.	DailyMed · Drugs@FDA
Ozempic (tablets)	Semaglutide	Novo Nordisk (NDA 213051)	Tablet, oral	In adults with type 2 diabetes: with diet and exercise, to improve glycemic control; and to reduce the risk of major adverse cardiovascular events in those at high risk for them.	DailyMed (shared with Rybelsus) · Drugs@FDA
Rybelsus	Semaglutide	Novo Nordisk (NDAs 213051 and 213182)	Tablet, oral	The same as Ozempic tablets: the two brands share one label.	DailyMed · Drugs@FDA: 213051, 213182
Wegovy (injection)	Semaglutide	Novo Nordisk (NDA 215256)	Injection (solution), subcutaneous	With a reduced-calorie diet and increased physical activity: to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight; to reduce excess body weight and maintain that reduction long term in adults and children 12 and older with obesity, and in adults with overweight and at least one weight-related condition; and to treat noncirrhotic MASH (a liver condition) with moderate to advanced liver fibrosis in adults, under FDA's accelerated approval.	DailyMed (shared with Wegovy tablets) · Drugs@FDA
Wegovy (tablets)	Semaglutide	Novo Nordisk (NDA 218316)	Tablet, oral	With a reduced-calorie diet and increased physical activity: to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight; and to reduce excess body weight and maintain that reduction long term in adults with obesity, or with overweight and at least one weight-related condition.	DailyMed · Drugs@FDA
Mounjaro	Tirzepatide	Eli Lilly and Company (NDA 215866)	Injection (solution), subcutaneous	With diet and exercise, to improve glycemic control in adults and children 10 and older with type 2 diabetes; and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for them.	DailyMed · Drugs@FDA
Zepbound	Tirzepatide	Eli Lilly and Company (NDA 217806)	Injection (solution), subcutaneous	With a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain that reduction long term in adults with obesity, or with overweight and at least one weight-related condition; and to treat moderate to severe obstructive sleep apnea in adults with obesity.	DailyMed · Drugs@FDA

"Approved use" is a shortened, plain-English summary of section 1 (Indications and Usage) of each label. The label's own text is what counts, so open it to read the full wording, including any limitations of use.

Drugs@FDA also lists some pens under their own names, such as Mounjaro KwikPen, Zepbound KwikPen and Wegovy FlexTouch. Each one sits on its brand's application rather than having an application of its own.

Same active ingredient, different products

An FDA approval doesn't belong to an active ingredient. It belongs to a specific product: an application with its own dosage forms, routes and labeled uses. FDA approves a drug for the particular uses it reviewed, and those uses are the ones written in the label. That's why Ozempic and Wegovy, which both contain semaglutide, are approved for different things, and why the same is true of Mounjaro and Zepbound.

A single brand name can also cover more than one product:

Ozempic is now the name of an injection (NDA 209637) and of tablets (NDA 213051). They're on different applications, with different labels.
Wegovy injection and Wegovy tablets sit on separate applications, though DailyMed shows them on one combined label, and their approved uses differ. The injection's uses include MASH and children 12 and older. The tablets are approved for adults only, and not for MASH.

FDA's Drugs@FDA glossary explains that one drug can have more than one application number when it comes in different dosage forms or routes.

For your own records, write down the brand name and the form (a pen, a vial or a tablet, for example) exactly as they appear on your pharmacy label or carton, not just the active ingredient. Peptimes records the active ingredient; note the brand in the dose's notes. If you're unsure which product you were given, your pharmacist can tell you. Keeping records when you switch medicines or brands covers what else to note. For more on what approval covers, see what "FDA approved" means.

Compounded versions are not FDA-approved

Compounded semaglutide and compounded tirzepatide are not the products in the table. In FDA's own words, "compounded drugs are not FDA approved," and FDA doesn't review them for safety, effectiveness or quality before they're marketed. A compounded product doesn't share a brand's approval, even when it contains the same active ingredient. What "compounded" means covers this in more detail.

Why retatrutide isn't in the table

No retatrutide product is FDA-approved. It's an investigational compound: Drugs@FDA had no listing for it on October 25, 2026, and its Phase 3 clinical trials are registered on ClinicalTrials.gov. The Peptimes Library labels it "Phase 3 Trials". See tracking retatrutide in Peptimes, and clinical trial phases explained for what a phase means.

Check a product yourself

Find the brand name and form on your pharmacy label or carton.
Search for the brand in Drugs@FDA. On its application page, check that the Dosage Form/Route column matches what you have.
Open the label, on Drugs@FDA or DailyMed, and read section 1, Indications and Usage.
Check the revision date at the end of the label's Highlights. Labels change: Mounjaro's, for example, gained a new indication in August 2026.

Our guide to reading an FDA drug label walks through each section of a label, and both websites, step by step.

Keeping your own record in Peptimes

Peptimes is a private iPhone tracker for the medicines you already use, including semaglutide and tirzepatide. When you add one, you can search the Library by its active ingredient or its brand name. You log each dose with your own amount and the route (subcutaneous or oral for semaglutide, subcutaneous for tirzepatide), plus the injection site for injections. Dose History lists every dose you log, newest first, and you can export your records as CSV or JSON to bring to an appointment.

More on Peptimes as a GLP-1 tracker, the pages on tracking semaglutide and tirzepatide, and exporting your records for an appointment.

FAQ

Is Ozempic the same as Wegovy?

They contain the same active ingredient, semaglutide, but they're separate FDA-approved products, with separate applications and labels, approved for different uses. Whether either is right for you is a question for your prescriber.

Is Mounjaro the same as Zepbound?

Both contain tirzepatide and both come from Eli Lilly and Company, but they're separate products with separate applications and labels, approved for different uses. The table shows each one's approved use.

Is compounded semaglutide or tirzepatide FDA-approved?

No. FDA states that compounded drugs are not FDA-approved, and that it doesn't review them for safety, effectiveness or quality before they're marketed.

Sources

FDA, Drugs@FDA, NDA 209637 (Ozempic, semaglutide injection), checked 25 Oct 2026: applicant Novo Nordisk ("NOVO"), solution for subcutaneous use, prescription; latest action 27 Aug 2026 (SUPPL-44, carton and container labels).
FDA, Drugs@FDA, NDA 213051 (Ozempic tablets and Rybelsus), checked 25 Oct 2026: both brand names listed as oral tablets on one application; latest label 30 Jan 2026 (SUPPL-30).
FDA, Drugs@FDA, NDA 213182 (Rybelsus), checked 25 Oct 2026: applicant Novo Nordisk Inc, oral tablets.
FDA, Drugs@FDA, NDA 215256 (Wegovy injection, Wegovy FlexTouch), checked 25 Oct 2026: solution for subcutaneous use; the presentation names on the application.
FDA, Drugs@FDA, NDA 218316 (Wegovy tablets), checked 25 Oct 2026: oral tablets, separate application from the injection.
FDA, Drugs@FDA, NDA 215866 (Mounjaro), checked 25 Oct 2026: applicant Eli Lilly and Co, subcutaneous solution, the Mounjaro and Mounjaro KwikPen names on the application; SUPPL-44 "Efficacy-New Indication" on 27 Aug 2026.
FDA, Drugs@FDA, NDA 217806 (Zepbound), checked 25 Oct 2026: applicant Eli Lilly and Co, subcutaneous solution, the Zepbound and Zepbound KwikPen names on the application.
FDA, openFDA drugsfda endpoint, semaglutide and tirzepatide searches, checked 25 Oct 2026: completeness check (six semaglutide applications, one of them tentative; two tirzepatide applications).
FDA, openFDA drugsfda endpoint, retatrutide search, checked 25 Oct 2026: no matching records.
NLM DailyMed, OZEMPIC (semaglutide) injection label, Novo Nordisk, Revised 5/2026, checked 25 Oct 2026: section 1 indications.
NLM DailyMed, OZEMPIC (oral semaglutide) tablets and RYBELSUS label, Novo Nordisk, Revised 1/2026, checked 25 Oct 2026: one shared label and one set of indications for both brands.
NLM DailyMed, WEGOVY (semaglutide) injection and tablets label, Novo Nordisk, Revised 6/2026, checked 25 Oct 2026: indications for each form, MASH under accelerated approval for the injection, tablets for adults only.
NLM DailyMed, MOUNJARO (tirzepatide) label, Eli Lilly and Company, Revised 8/2026, checked 25 Oct 2026: section 1 indications.
NLM DailyMed, ZEPBOUND (tirzepatide) label, Eli Lilly and Company, Revised 8/2026, checked 25 Oct 2026: section 1 indications.
FDA, "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss" (content current as of 10/01/2026), checked 25 Oct 2026: the quotation that compounded drugs are not FDA approved; FDA doesn't review them for safety, effectiveness or quality before marketing.
FDA, "Compounding and the FDA: Questions and Answers" (content current as of 09/16/2025), checked 25 Oct 2026: compounded drugs are not FDA-approved and are distinct from FDA-approved generics.
FDA, "Understanding Unapproved Use of Approved Drugs 'Off Label'" (content current as of 02/05/2018), checked 25 Oct 2026: approval reflects FDA's judgment about specific uses, which the approved labeling states.
FDA, Drugs@FDA Glossary of Terms, checked 25 Oct 2026: one drug can have several application numbers for different dosage forms or routes.
US Government Publishing Office, 21 CFR 201.57 (annual edition revised as of 1 Apr 2025), checked 25 Oct 2026: the revision date sits at the end of Highlights.
ClinicalTrials.gov (NIH), studies of retatrutide filtered to Phase 3, checked 25 Oct 2026: Phase 3 trials of retatrutide sponsored by Eli Lilly and Company are registered.

Coming soon to the App Store

See planned pricing